🔗 Share this article World Health Organization Issues Concern Over Severe Lack of Weight-Loss Injections Fewer than 10% of people that would benefit from GLP-1 drugs including Wegovy can access them, caution the World Health Organization as it releases its initial recommendations on the medications. Given over a billion individuals worldwide now obese, it is urging broader and more equitable access to this class of drugs. Per estimates, over two billion could be living with obesity by 2030 if no action is taken. "Our latest guidelines affirms that excess weight is a lifelong illness that can be treated with holistic and continuous care," remarked the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and supply-chain constraints are major obstacles to universal access to the injections that can aid individuals in losing significant body mass, notes the body. GLP-1 Therapy Shortage Even in the present best projected case, the production of such drugs might only reach around 100 million people – fewer than 10% of eligible patients, as stated by the health organization. The recommendation calls on nations and manufacturers to expand access, by strategies including patent sharing. Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026. The Way Weight-Loss Injections Work The injections mimick a natural hormone to reduce digestion speed, reduce hunger and boost feelings of fullness so people eat less. Patients commonly see weight reduction in the initial weeks of beginning the once-weekly jabs. Research suggests people may see weight return a year later of halting the drug, as their typical appetite come back. Being carrying excess weight raises your chance for contracting medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies. Obesity concerns individuals in every country and was associated with over three and a half million fatalities worldwide in 2024, as per the WHO.
Fewer than 10% of people that would benefit from GLP-1 drugs including Wegovy can access them, caution the World Health Organization as it releases its initial recommendations on the medications. Given over a billion individuals worldwide now obese, it is urging broader and more equitable access to this class of drugs. Per estimates, over two billion could be living with obesity by 2030 if no action is taken. "Our latest guidelines affirms that excess weight is a lifelong illness that can be treated with holistic and continuous care," remarked the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and supply-chain constraints are major obstacles to universal access to the injections that can aid individuals in losing significant body mass, notes the body. GLP-1 Therapy Shortage Even in the present best projected case, the production of such drugs might only reach around 100 million people – fewer than 10% of eligible patients, as stated by the health organization. The recommendation calls on nations and manufacturers to expand access, by strategies including patent sharing. Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026. The Way Weight-Loss Injections Work The injections mimick a natural hormone to reduce digestion speed, reduce hunger and boost feelings of fullness so people eat less. Patients commonly see weight reduction in the initial weeks of beginning the once-weekly jabs. Research suggests people may see weight return a year later of halting the drug, as their typical appetite come back. Being carrying excess weight raises your chance for contracting medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies. Obesity concerns individuals in every country and was associated with over three and a half million fatalities worldwide in 2024, as per the WHO.